ReviewAntiviral research2017
The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis.
Review in Antiviral research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05386485 (FUNCTION Study), which is not on this map. Cited by 116 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FUNCTION Study: Follow- Up Study iN SARS-CoV-2 infecTION. Long-term Impact on Cardiopulmonary Function and Quality of Life in Patients Recovered From SARS-CoV-2 Infection in Lima, Peru
Who cites it
116 citing papers in PubMed, 2 syntheses or guidelines pooled it, 195 citations in OpenAlex.
- Sequelae of COVID-19 among previously hospitalized patients up to 1 year after discharge: a systematic review and meta-analysis.Infection · 2022Pooled it
- Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis.PulmonologyPooled it
- Acute estradiol and progesterone therapy in hospitalized adults to reduce COVID-19 severity: a randomized control trial.Scientific reports · 2024Trial
- Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9.Scientific reports · 2021Trial
- Investigating the role of EGFR signalling in muscle dystrophies: implications for Duchenne muscular dystrophy.Cell death & disease · 2026Article
- Medical ozone: mechanisms, biological effects and clinical evidence-a narrative review.Frontiers in medicine · 2026Review
- Self-assembled extracellular matrix-lipid nanoparticle composite for site-specific siRNA delivery to improve cardiac repair post-myocardial infarction.Materials today. Bio · 2025Article
- Airway epithelial SARS-CoV-2 infectious and repair responses: relationships to age, sex, and post-COVID pulmonary syndromes.bioRxiv : the preprint server for biology · 2025Article
- Breathless Aftermath: Post-COVID-19 Pulmonary Fibrosis.Viruses · 2025Review
- 4-Hydroxychalcone Inhibits Human Coronavirus HCoV-OC43 by Targeting EGFR/AKT/ERK1/2 Signaling Pathway.Viruses · 2025Article
- Neurobiology of COVID-19-Associated Psychosis/Schizophrenia: Implication of Epidermal Growth Factor Receptor Signaling.Neuropsychopharmacology reports · 2025Review
- Investigating the Post-Mortem Risk of Transmission of SARS-CoV-2 Virus in Cadaveric Tissues: A Systematic Review of the Literature.Microorganisms · 2025Review
- Article
- SPIKENET: An Evidence-Based Therapy for Long COVID.Viruses · 2024Review
- SARS-CoV-2 aberrantly elevates mitochondrial bioenergetics to induce robust virus propagation.Signal transduction and targeted therapy · 2024Article
- Lung Diffusion Capacity in Patients With Bilateral COVID-19 Pneumonia: A Three-Month Follow-Up Study.Cureus · 2024Article
- Impact of the immune profiles of hypertensive patients with and without obesity on COVID-19 severity.International journal of obesity (2005) · 2024Article
- Review
- New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic.Frontiers in immunology · 2024Review
- View Score: An early warning score to detect possible complications among COVID-19 patients.Journal of family medicine and primary care · 2023Article
56 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Many survivors of the 2003 outbreak of severe acute respiratory syndrome (SARS) developed residual pulmonary fibrosis with increased severity seen in older patients. Autopsies of patients that died from SARS also showed fibrosis to varying extents. Pulmonary fibrosis can be occasionally seen as a consequence to several respiratory viral infections but is much more common after a SARS coronavirus (SARS-CoV) infection. Given the threat of future outbreaks of severe coronavirus disease, including Middle East respiratory syndrome (MERS), it is important to understand the mechanisms responsible for pulmonary fibrosis, so as to support the development of therapeutic countermeasures and mitigate sequelae of infection. In this article, we summarize pulmonary fibrotic changes observed after a SARS-CoV infection, discuss the extent to which other respiratory viruses induce fibrosis, describe available animal models to study the development of SARS-CoV induced fibrosis and review evidence that pulmonary fibrosis is caused by a hyperactive host response to lung injury mediated by epidermal growth factor receptor (EGFR) signaling. We summarize work from our group and others indicating that inhibiting EGFR signaling may prevent an excessive fibrotic response to SARS-CoV and other respiratory viral infections and propose directions for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.